Loading clinical trials...
Loading clinical trials...
Anlotinib Plus Etoposide and Carboplatin as First-line Treatment for Extensive-stage Small Cell Lung Cancer: A Single Arm Phase II Trial
Conditions
Interventions
Anlotinib hydrochloride
Etoposide
+1 more
Locations
1
China
Shanghai Chest hospital
Shanghai, Shanghai Municipality, China
Start Date
May 1, 2019
Primary Completion Date
September 1, 2021
Completion Date
January 1, 2022
Last Updated
December 24, 2020
NCT07486219
NCT06305754
NCT05098132
NCT06731413
NCT04585750
NCT04826341
Lead Sponsor
Shanghai Chest Hospital
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions